The Sculptique Aesthetics
The GLOW Peptide Blend: GHK-Cu, BPC-157 and TB-500 in One Vial
GLOW is a seller's name for GHK-Cu, BPC-157 and TB-500 mixed together. No study has tested that trio. Topical copper-peptide data do not transfer to an injected blend.

GLOW is three peptides and a marketing word. I can discuss GHK-Cu, BPC-157 and TB-500 as separate questions. I cannot point you to a trial of the mixture, because that trial has not been done.
— Dr. Aamod Rao
If Wolverine is the recovery nickname, GLOW is the beauty nickname built on top of it. Sellers use GLOW for a freeze-dried blend of three peptides: GHK-Cu, BPC-157 and TB-500. Add KPV and the same market calls it KLOW. None of these names is a molecule. None of them is a standard set by a regulator or a journal.
Search interest in 2026 has treated Wolverine, GLOW, NAD+, retatrutide and tirzepatide as one trend. They are not one class of drug. This page is only about the three-peptide blend.
What people are actually buying
A common label on a "70 mg" GLOW vial reads roughly 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. Other sellers print other splits, including smaller vials with different ratios. A printed split is a claim about that batch. It is not a law of nature, and it is not a certificate you can assume for the next bottle with the same word on it.
Independent of the ratio, three facts stay put:
- GHK-Cu is a copper complex of a human tripeptide, studied for skin, collagen signals and repair. The human trials that exist are mostly creams, not injections. We use supervised GHK-Cu and explain that difference in GHK-Cu and AHK-Cu.
- BPC-157 is a 15-amino-acid peptide with animal data in tissue injury and a thin human record. BPC-157.
- TB-500 is a short fragment of thymosin beta-4, discussed for cell movement. It is not the same substance as full-length thymosin beta-4. TB-500.
The two-peptide version of this story is the Wolverine blend. The four-peptide version is KPV and KLOW.
What "no trial of the blend" means
There is no published study, in people or in animals, that tests GHK-Cu plus BPC-157 plus TB-500 as the combination sitting in these vials. You can read papers on each name. You cannot add the papers up and get a result for the mixture.
That matters for two reasons.
Effects do not stack like a shopping list. In tendon work on BPC-157 and a thymosin fragment, giving both has not reliably beaten giving one. GHK-Cu may push on matrix and inflammation pathways the other two do not, which is the interesting scientific question. It is still a question.
Harms do not stay politely inside each paper either. An injected copper peptide, an injected repair peptide and an injected thymosin fragment share a needle, a purity problem and an immune system. Topical GHK-Cu evidence does not answer that. A cream on the cheek is a different exposure from a subcutaneous blend.
US compounding discussions in 2026 looked at several of these peptides one by one. A committee vote about a single substance is not a licence for a three-drug vial, and it is not Indian approval.
How we handle the request in clinic
Patients ask for GLOW because they want skin and recovery in one step. The honest split is:
Skin quality has options we can examine you for: GHK-Cu, babyGLOW, polynucleotides, and the comparison in peptides versus surgery for ageing skin.
Tissue-repair peptides, if we use them, are prescribed as named products with a reason, a diluent and a follow-up. Mixing three research powders because a reel used the word glow is not that appointment.
Water still only changes concentration. If you already have a blend vial, read bacteriostatic water before you decide that a larger syringe is a smaller risk. Then bring the vial in rather than reconstituting from a screenshot.
Frequently asked questions
Typically GHK-Cu, BPC-157 and TB-500. The word is commercial. A widely copied label is about 50 mg, 10 mg and 10 mg. Your vial may not match that label, and the label may not match the powder.
Wolverine usually means BPC-157 and TB-500. GLOW adds GHK-Cu. KLOW adds KPV as well. Each added name is another untested combination, not a stronger version of a proven one.
They apply to the creams and serums that were tested. They do not establish what an injected three-peptide blend does to a face, a tendon, or a lab panel.
No validated dose exists, because the blend itself has not been studied. We will not publish one. Supervised use of a single peptide we actually stock is a different decision, made in person.
Hair and skin are reasons people buy the vial. They are not indications earned by a trial of this mixture. Hair loss has its own examination. Skin has its own. A blend is not a shortcut between them.
Ask for the three names, not the nickname
If you want a skin plan, book that. If you have a GLOW vial already, bring it and we will tell you what the label can and cannot support.
Book a consultation · GHK-Cu · Peptide therapy
Sources
Checked 18 November 2026:
- Seller-defined composition, commonly GHK-Cu with BPC-157 and TB-500, often labelled near 50 mg / 10 mg / 10 mg in a 70 mg vial. Ratios vary. No peer-reviewed study of the three-peptide product was identified in reviews current to autumn 2026.
- Human GHK-Cu data are largely topical. They do not transfer to an injected blend. See the clinic GHK-Cu pages linked above.
- July 2026 US advisory discussion of individual peptides is not an approval of combination products. https://www.healthed.com.au/clinical_articles/peptide-use-in-australia-what-gps-need-to-know/
This article is for educational purposes only. It is not medical advice and does not replace a consultation with a qualified clinician.








